Industry Trends Show Immunology Biosimilars Market Set to Expand at 12.9% CAGR Until 2029

Global Immunology Biosimilars Market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Immunology Biosimilars Market Valued at Present and by 2029?

There has been a swift expansion in the size of the immunology biosimilars market in the past few years. The market is anticipated to escalate from $7.38 billion in 2024 to $8.35 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.1%. Factors causing this historic increase include enhanced acceptance of biosimilars, mounting demands for cost-efficient biologics, the surge in autoimmune diseases, growing patient knowledge regarding biosimilar treatments, and augmented regulatory backing for the approval of biosimilars.

In the coming years, the immunology biosimilars market is predicted to experience swift expansion, reaching a value of $13.57 billion in 2029 with a compound annual growth rate (CAGR) of 12.9%. The increased growth in the forecast period can be linked to a heightened emphasis on lowering medical costs, the upsurge of chronic inflammatory conditions, a broader reach in new markets, amplified support for biosimilar interchangeability, and significant investments made by pharmaceutical firms. Trends identified for the forecast period encompass progress in biologics production technology, partnerships in research and development, creation of advanced biosimilars, innovative delivery mechanism, and the integration of artificial intelligence in the process of biosimilar development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25789&type=smp

#What Drivers Are Influencing Growth In The Immunology Biosimilars Market?

The upward trend in chronic immunological conditions is anticipated to drive the growth of the immunology biosimilars market. These conditions are persistent disorders where the immune system either attacks the body’s tissues or fails to offer it effective protection. This rise is attributed to the increasing number of individuals suffering from enduring immune system disorders, which necessitate consistent treatment, active disease management, and sustainable healthcare support. Immunology biosimilars provide affordable and efficient treatment alternatives for chronic immunological conditions, thereby enhancing long-term disease control and improving patient access to crucial therapies that manage immune system dysfunction. For instance, the Australian Institute of Health and Welfare, a governmental organization based in Australia, reported in June 2024 that rheumatoid arthritis, a systemic autoimmune disease, affected approximately 514,000 individuals (2.0%) in 2022, with 2.5% of females and 1.6% of males living with the condition. Thus, the escalating prevalence of chronic immunological conditions is propelling the immunology biosimilars market’s growth.

What Are The Main Segments Identified In The Immunology Biosimilars Market Research?

The immunology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins, Interferons, Other Biosimilar Immunomodulators

2) By Disease: Inflammatory Bowel Disease, Arthritis, Other Diseases

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End User: Hospitals, Clinics, Homecare Settings, Ambulatory Surgical Centers (ASCs)

Subsegments:

1) By Monoclonal Antibodies: Anti-Tumor Necrosis Factor Agents, Anti-Interleukin-6 Agents, Anti-Cluster of Differentiation 20 Agents, Anti-Interleukin-12/23 Agents, Other Monoclonal Antibodies

2) By Fusion Proteins: Etanercept Biosimilars, Other Fusion Protein Biosimilars

3) By Recombinant Proteins: Recombinant Human Insulin, Recombinant Human Growth Hormone, Recombinant Human Erythropoietin, Other Recombinant Protein Biosimilars

4) By Interferons: Interferon Alpha, Interferon Beta, Interferon Gamma

5) By Other Biosimilar Immunomodulators: Interleukin Inhibitors, Janus Kinase Inhibitors, Other Immunomodulatory Biosimilars

What Are The Leading Trends And Opportunities In The Immunology Biosimilars Sector?

Firms in the immunology biosimilars sector, such as Sandoz Group AG and Samsung Bioepis Co. Ltd., are concentrating on the advancement of high-tech biosimilar innovations including possible interchangeability designation, improved stable formulations, and new forms of delivery. This is aimed at providing patients with more practical and efficient therapeutic alternatives. Predicted interchangeability designation reflects that the biosimilar is set to satisfy regulatory requirements, making it eligible for exchange with the reference biologic at the pharmacy without intervention from the prescriber. For example, Sandoz Group AG, a Swiss pharmaceutical firm, in partnership with Samsung Bioepis Co. Ltd., a biopharmaceutical company from South Korea, unveiled Pyzchiva (ustekinumab-ttwe), a biosimilar to Stelara, for chronic autoimmune disorders therapy such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, in February 2025. This launch signifies Sandoz’s dedication to amplifying the accessibility of immunology biosimilars with an economical, patient-focused therapy featuring multiple dose options, increased stability, and a unique re-refrigeration capacity after the initial cooling process.

Which Companies Play A Key Role In The Development Of The Immunology Biosimilars Market?

Major companies operating in the immunology biosimilars market are Pfizer Inc., Novartis AG, LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Stada Arzneimittel AG, Cipla Ltd., Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Gedeon Richter Plc, Celltrion Inc., Biocon Ltd., Innovent Biologics Inc., Biocad, Mabion S.A.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/immunology-biosimilars-global-market-report

What Are The Key Regional Developments Shaping The Immunology Biosimilars Market?

North America was the largest region in the immunology biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25789&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model